Lidanserin

Lidanserin
Clinical data
ATC code	None;
Identifiers
	IUPAC name 4-(3-{3-[4-(4-fluorobenzoyl)-1-piperidinyl]propoxy}-4-methoxyphenyl)-2-pyrrolidinone;
CAS Number	73725-85-6;
PubChem CID	68919;
ChemSpider	62146;
UNII	80O1E9JZLN;
CompTox Dashboard (EPA)	DTXSID60868269 ;
Chemical and physical data
Formula	C26H31FN2O4
Molar mass	454.542 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES Fc1ccc(cc1)C(=O)C4CCN(CCCOc2cc(ccc2OC)C3CC(=O)NC3)CC4;
	InChI InChI=1S/C26H31FN2O4/c1-32-23-8-5-20(21-16-25(30)28-17-21)15-24(23)33-14-2-11-29-12-9-19(10-13-29)26(31)18-3-6-22(27)7-4-18/h3-8,15,19,21H,2,9-14,16-17H2,1H3,(H,28,30); Key:JDYWZVJXSMADHP-UHFFFAOYSA-N;

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Lidanserin (INN; ZK-33,839) is a drug which acts as a combined 5-HT_2A and α₁-adrenergic receptor antagonist.^[1] It was developed as an antihypertensive agent but was never marketed.^[1]

References

^ ^a ^b Allen RC (1989). Annual Reports in Medicinal Chemistry. Academic Press. p. 56. ISBN 978-0-12-040524-4. Retrieved 6 May 2012.

This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it.

[Allen1989-1] Allen RC (1989). Annual Reports in Medicinal Chemistry. Academic Press. p. 56. ISBN 978-0-12-040524-4. Retrieved 6 May 2012.

[1]

See also

References